-
The street drug alarming physicians that's 10x more potent than fentanyl
Nitazenes, a group of highly potent, synthetic drugs made in the 1950s as opioid analgesics, are becoming more commonly used in street drugs. In some cases, it can even be 10 times more potent than fentanyl. -
Novartis reports success in phase 3 trial of drug for rare kidney disease
Pharmaceutical maker and biotechnology company Novartis is reporting positive topline results from a phase 3 trial of a drug to treat a rare kidney disease. -
9 hospitals cleared to deliver new CRISPR-based sickle cell treatment
The FDA made a historic approval Dec. 8 when it cleared Casgevy, the nation's first medicine based on CRISPR gene-editing technology, as a treatment for sickle cell disease. Its makers are now working with hospitals to establish a network of specialized treatment centers, and so far nine have been authorized to deliver the treatment. -
FDA approves nation's 1st CRISPR gene therapy to treat sickle cell disease: Experts react
On Dec. 8, the FDA approved the nation's first medicine based on CRISPR gene-editing technology to be used as a treatment for patients with sickle cell disease, a major scientific advancement that opens the door for future gene therapy approvals for inherited disorders. -
Walgreens expands testing, treatment options for COVID-19, flu
Walgreens will expand treatment and testing options for COVID-19 and the flu, the company announced Dec. 7. -
Biden administration OKs ability to seize drug patents to lower costs
After a nearly nine-month review, the Biden administration has determined it has the authority to seize the patents of certain high-priced drugs developed with taxpayer funds — a policy known as march-in rights. -
8 most influential drug approvals in 2023: GoodRx
Out of the hundreds of new drugs entering the U.S. market, eight made tailwinds in the healthcare industry, according to GoodRx. -
Adherence to Wegovy far outpaces older weight loss drugs: Cleveland Clinic study
Patients taking Novo Nordisk's weight loss drug Wegovy in 2021 and 2022 were three times more likely to continue taking the medication a year later compared to older weight loss therapies, according to a study published Dec. 6 in Obesity. -
How 2 pharmacy leaders became hospital CEOs
As more systems create a C-suite role for pharmacy leaders, health systems and hospitals are increasingly promoting these executives to non-pharmacy roles, such as CEO. -
Eli Lilly obesity drug hits pharmacy shelves
Zepbound, a newly approved obesity drug from Eli Lilly, hit the market Dec. 5. -
The Mark Cuban effect on drug pricing
In January 2022, entrepreneur and "Shark Tank" star Mark Cuban launched an online pharmacy that priced 100 medications by their manufacturing fee, a 15% markup, and a shipping and handling fee. Less than two years later, Express Scripts and CVS are following suit. -
Most of ChatGPT's answers to drug questions are wrong: Study
Nearly 75% of ChatGPT's answers to drug-related questions are incomplete or wrong, according to a study conducted at Brookville, N.Y.-based Long Island University. -
3 patients die in cancer drug trial
Three patients reportedly died in a Merus clinical trial of a new lung cancer treatment. -
Elevance to launch digital pharmacy under Carelon
Elevance Health is launching CarelonRx Pharmacy, a digital and home delivery pharmacy subsidiary, in 2024. -
Cancer society urges lawmakers to resolve drug shortages
With 16 ongoing oncology drug shortages disrupting patient care, a cancer society is asking lawmakers to push legislation aimed at systemic fixes to drug shortages. -
CVS to revamp drug pricing model
CVS Pharmacy is taking a cue from Mark Cuban Cost Plus Drugs and will launch a pharmacy reimbursement model built around a drug's cost, a pharmacy services fee and a set markup. -
Why non-union pharmacists are protesting
A tectonic shift in mindsets is inciting non-union pharmacists and other healthcare workers to protest, The New York Times reported Dec. 4. -
After cyberattack, patients struggle to fill scripts
Patients of Lovelace Health System say they can't refill their prescriptions as the Albuquerque, N.M.-based system recovers from a cyberattack, Albuquerque Journal reported Dec. 1. -
Lawmakers probe FDA's decongestant decision
House Republicans are investigating the FDA's regulation of a common decongestant found in over-the-counter cold medicines that the agency recently determined to be ineffective, The Hill reported Dec. 4. -
Eli Lilly drug gets new approval for blood cancer
The FDA has granted approval to Eli Lilly and Company's drug Jaypirca, a therapy to treat chronic lymphocytic leukemia or small lymphocytic lymphoma.
Page 23 of 50